To be fair, I was wrong about one thing. I thought the CR would be at 2c or less. Perhaps next year. Well done ANP for reinventing ATL1102 again. The IIL situation does highlight how much there is to lose for any potential partners who would stump up to continue development.
News: ANP Antisense Therapeutics says ATL1102 for MS Phase IIb IND submitted to FDA for review, page-22
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $90.15M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.0¢ | $47.27K | 463.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 319942 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 86442 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |